PharmaBlock Sciences (Nanjing), Inc. (SHE:300725)
China · Delayed Price · Currency is CNY 36.71
-0.89 (-2.37%)
Mar 19, 2026, 3:04 PM CST
SHE:300725 Revenue
PharmaBlock Sciences (Nanjing) had revenue of 499.33M CNY in the quarter ending September 30, 2025, with 30.36% growth. This brings the company's revenue in the last twelve months to 1.98B, up 26.78% year-over-year. In the year 2024, PharmaBlock Sciences (Nanjing) had annual revenue of 1.69B, down -2.12%.
Revenue (ttm)
1.98B
Revenue Growth
+26.78%
P/S Ratio
4.42
Revenue / Employee
806.43K
Employees
2,455
Market Cap
8.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.69B | -36.58M | -2.12% |
| Dec 31, 2023 | 1.73B | 130.50M | 8.18% |
| Jan 1, 2023 | 1.59B | 393.07M | 32.71% |
| Dec 31, 2021 | 1.20B | 179.40M | 17.55% |
| Dec 31, 2020 | 1.02B | 360.00M | 54.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 27.28B |
| Harbin Pharmaceutical Group | 15.94B |
| KPC Pharmaceuticals,Inc. | 6.58B |
| Shandong Lukang Pharmaceutical | 6.19B |
| Zhejiang Xianju Pharmaceutical | 3.59B |
| Tianjin Ringpu Bio-Technology | 3.37B |
| Guangxi Wuzhou Zhongheng Group | 2.29B |
| Guilin Sanjin Pharmaceutical | 2.08B |